Capital World Investors held its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 137,700 shares of the biopharmaceutical company’s stock at the close of the second quarter. Capital World Investors owned approximately 0.15% of Alnylam Pharmaceuticals worth $10,983,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. QS Investors LLC boosted its holdings in Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 900 shares during the period. CIBC Asset Management Inc bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $221,000. Neuberger Berman Group LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $229,000. Capstone Asset Management Co. bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $232,000. Finally, Hemenway Trust Co LLC bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at $235,000. 94.25% of the stock is owned by institutional investors.
Several research analysts have commented on ALNY shares. ValuEngine raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. BidaskClub raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 13th. Piper Jaffray Companies reissued an “overweight” rating and issued a $126.00 price target (up from $116.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, June 21st. Jefferies Group LLC reissued a “buy” rating and issued a $102.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, June 22nd. Finally, Needham & Company LLC raised their price target on shares of Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the company a “buy” rating in a report on Tuesday, June 27th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $100.80.
TRADEMARK VIOLATION WARNING: “Capital World Investors Holds Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/10/11/capital-world-investors-holds-holdings-in-alnylam-pharmaceuticals-inc-alny.html.
In other news, President Barry E. Greene sold 76,815 shares of the stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the sale, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President Barry E. Greene sold 85,316 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.
Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 122.29 on Wednesday. The firm has a 50 day moving average of $96.96 and a 200-day moving average of $76.19. Alnylam Pharmaceuticals, Inc. has a 52-week low of $31.38 and a 52-week high of $125.96. The stock’s market cap is $11.22 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. During the same period in the prior year, the company posted ($1.05) EPS. The company’s revenue was up 82.9% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.20) earnings per share for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.